Logo image of ZURA

ZURA BIO LTD (ZURA) Stock Fundamental Analysis

USA - NASDAQ:ZURA - KYG9TY5A1016 - Common Stock

3.93 USD
+0.24 (+6.5%)
Last: 10/27/2025, 8:00:03 PM
3.94 USD
+0.01 (+0.25%)
Pre-Market: 10/28/2025, 4:05:05 AM
Fundamental Rating

2

ZURA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ZURA as it has an excellent financial health rating, but there are worries on the profitability. ZURA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ZURA has reported negative net income.
In the past year ZURA has reported a negative cash flow from operations.
In multiple years ZURA reported negative net income over the last 5 years.
In the past 5 years ZURA always reported negative operating cash flow.
ZURA Yearly Net Income VS EBIT VS OCF VS FCFZURA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

ZURA has a Return On Assets (-41.46%) which is in line with its industry peers.
The Return On Equity of ZURA (-51.96%) is better than 65.92% of its industry peers.
Industry RankSector Rank
ROA -41.46%
ROE -51.96%
ROIC N/A
ROA(3y)-30.48%
ROA(5y)N/A
ROE(3y)-48.32%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZURA Yearly ROA, ROE, ROICZURA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ZURA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZURA Yearly Profit, Operating, Gross MarginsZURA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for ZURA has been increased compared to 1 year ago.
There is no outstanding debt for ZURA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ZURA Yearly Shares OutstandingZURA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M
ZURA Yearly Total Debt VS Total AssetsZURA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 2.66 indicates that ZURA is not a great score, but indicates only limited risk for bankruptcy at the moment.
ZURA's Altman-Z score of 2.66 is fine compared to the rest of the industry. ZURA outperforms 67.04% of its industry peers.
There is no outstanding debt for ZURA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.66
ROIC/WACCN/A
WACCN/A
ZURA Yearly LT Debt VS Equity VS FCFZURA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

ZURA has a Current Ratio of 8.40. This indicates that ZURA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ZURA (8.40) is better than 75.09% of its industry peers.
A Quick Ratio of 8.40 indicates that ZURA has no problem at all paying its short term obligations.
With a decent Quick ratio value of 8.40, ZURA is doing good in the industry, outperforming 75.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.4
Quick Ratio 8.4
ZURA Yearly Current Assets VS Current LiabilitesZURA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for ZURA have decreased strongly by -28.57% in the last year.
EPS 1Y (TTM)-28.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ZURA will show a very negative growth in Earnings Per Share. The EPS will decrease by -13.58% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-34.06%
EPS Next 2Y-20.49%
EPS Next 3Y-13.58%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZURA Yearly Revenue VS EstimatesZURA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 5M 10M 15M
ZURA Yearly EPS VS EstimatesZURA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ZURA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ZURA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZURA Price Earnings VS Forward Price EarningsZURA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZURA Per share dataZURA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

ZURA's earnings are expected to decrease with -13.58% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.49%
EPS Next 3Y-13.58%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZURA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZURA BIO LTD

NASDAQ:ZURA (10/27/2025, 8:00:03 PM)

Premarket: 3.94 +0.01 (+0.25%)

3.93

+0.24 (+6.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-17 2025-11-17/bmo
Inst Owners51.22%
Inst Owner ChangeN/A
Ins Owners7.49%
Ins Owner Change0%
Market Cap255.53M
Revenue(TTM)N/A
Net Income(TTM)-65425000
Analysts84.62
Price Target13.6 (246.06%)
Short Float %5.58%
Short Ratio1.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.98%
Min EPS beat(2)-17.47%
Max EPS beat(2)11.5%
EPS beat(4)2
Avg EPS beat(4)-18.96%
Min EPS beat(4)-106.68%
Max EPS beat(4)36.82%
EPS beat(8)5
Avg EPS beat(8)6.56%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.66%
EPS NY rev (1m)0%
EPS NY rev (3m)4.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.03
P/tB 2.03
EV/EBITDA N/A
EPS(TTM)-0.72
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-0.67
FCFYN/A
OCF(TTM)-0.66
OCFYN/A
SpS0
BVpS1.94
TBVpS1.94
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -41.46%
ROE -51.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.48%
ROA(5y)N/A
ROE(3y)-48.32%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 410.35%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.4
Quick Ratio 8.4
Altman-Z 2.66
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-28.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-34.06%
EPS Next 2Y-20.49%
EPS Next 3Y-13.58%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-74.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-197.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-390%
OCF growth 3YN/A
OCF growth 5YN/A

ZURA BIO LTD / ZURA FAQ

Can you provide the ChartMill fundamental rating for ZURA BIO LTD?

ChartMill assigns a fundamental rating of 2 / 10 to ZURA.


What is the valuation status for ZURA stock?

ChartMill assigns a valuation rating of 0 / 10 to ZURA BIO LTD (ZURA). This can be considered as Overvalued.


Can you provide the profitability details for ZURA BIO LTD?

ZURA BIO LTD (ZURA) has a profitability rating of 1 / 10.


Can you provide the financial health for ZURA stock?

The financial health rating of ZURA BIO LTD (ZURA) is 7 / 10.